Kevin F Boehnke, PhD

 Kevin F. Boehnke
Assistant Professor of Anesthesiology
Program Associate, Anesthesiology, Medical School
[email protected]
Available to mentor
Kevin F Boehnke, PhD
Kevin F. Boehnke
Assistant Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Kevin Boehnke is an Assistant Professor in the Department of Anesthesiology and the Chronic Pain and Fatigue Research Center. He is also the Associate Director of the Michigan Psychedelic Center. Kevin received his doctorate from the University of Michigan School of Public Health in Environmental Health Sciences in 2017. He is also a yoga instructor. His current research focuses on therapeutic applications of cannabis and psychedelics. His goal is to rigorously assess appropriate use of these substances and to help address the public health harms caused by their criminalization.

    Qualifications
    • Postdoctoral Fellowship
      University of Michigan, Anesthesiology, Ann Arbor, United States
      2017 - 2018
      Postdoctoral Fellowship
    • PhD
      University of Michigan, School of Public Health, 1415 Washington Heights, Ann Arbor, MI, 48109, United States
      2012 - 2017
    • BS
      University of Michigan, Ann Arbor, MI, United States
      2005 - 2009

    Center Memberships
    • Center Member
      Opioid Research Institute

    Research Overview

    • Public Health
    • Medical cannabis and cannabinoids
    • Chronic pain management
    • Yoga
    • Science communication and engagement
    • Psychedelics

    Recent Publications

     See All Publications
    • Journal Article
      High stakes: how legal cannabis pricing impacts the illicit market.
      Hebert R, Boehnke KF, Joshi S. J Cannabis Res, 2026 Jun 6; DOI:10.1186/s42238-026-00455-3
      PMID: 42249514
    • Journal Article
      Assessing the Efficacy of Cannabinoid Compositions for Treating 3 Classes of Chronic Pain: A Real-World Evidence Study.
      Kruger DJ, Dautrich T, Hall B, Keeling K, Provost K, Boehnke KF. Clin Ther, 2026 May 15; DOI:10.1016/j.clinthera.2026.04.018
      PMID: 42140793
    • Journal Article
      Opioids and Cannabis: An Uncertain Combination?
      Boehnke KF. Anesthesiology, 2026 May 1; 144 (5): 1048 - 1050. DOI:10.1097/ALN.0000000000005958
      PMID: PMC13089812
    • Journal Article
      Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically.
      Aday JS, Glynos NG, Baker AK, Pouyan N, Smith T, Barron J, Herberholz M, Kruger DJ, Woolley JD, Boehnke KF. Sci Rep, 2026 Apr 15; DOI:10.1038/s41598-026-48084-3
      PMID: 41986543
    • Preprint
      High Stakes: How Legal Cannabis Pricing Impacts the Illicit Market
      Hebert R, Joshi S, Boehnke K. 2026 Mar 7; Research Square, DOI:10.21203/rs.3.rs-8950795/v1
    • Journal Article
      Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies.
      Haupt MJ, Pointe S, Boehnke KF, Aday JS. Prog Neuropsychopharmacol Biol Psychiatry, 2026 Feb 8; 111634 DOI:10.1016/j.pnpbp.2026.111634
      PMID: 41667049
    • Journal Article
      Blunted Psychedelic Drug Effects in Older Adults.
      Aday JS, Carhart-Harris RL, Boehnke KF. Am J Geriatr Psychiatry, 2026 Jan 11; DOI:10.1016/j.jagp.2026.01.007
      PMID: 41633886
    • Additional Scholarship
      What does cannabis 'rescheduling' mean for science and society?
      Boehnke K. 2026 Feb 6;

    Featured News & Stories
    Department News

    U-M Medical School study to provide insight into real-world trends around psychedelics in the U.S.

    A new University of Michigan Medical School study aims to better understand how Americans perceive and use psychedelics as these changes are enacted. The project has been awarded $3.3 million in funding from the National Institute on Drug Abuse, part of the National Institutes of Health.
         cannabis green leaf in glass
    Health Lab

    What does cannabis 'rescheduling' mean for science and society?

    Medical cannabis (marijuana) has been rescheduled on the federal level, which could open the door for much more research than was possible before. Four Michigan Medicine experts comment.
         man practicing yoga outside over blanket
    Health Lab

    Reframing the role of medications in chronic pain management

    An expert on pain management discusses why relying on medications to ease discomfort can easily backfire, and how people can avoid complete reliance on these types of drugs.
         mushrooms in a microscope
    Health Lab

    How cannabis and psilocybin might help some of the 50 million Americans experiencing chronic pain

    Recent developments represent a dramatic change from long standing federal policy around these substances that has historically criminalized their use and blocked or delayed research efforts into their therapeutic potential.
    Department News

    Daniel Clauw, MD, and Kevin Boehnke, PhD, featured in New York Times opinion piece

    How can patients heal from chronic pain? Daniel Clauw, MD, and Kevin Boehnke, PhD, provide insights in this New York Times opinion piece from Nicholas Kristof.